Tri-Solfen registered in New Zealand for sheep and cattle husbandry procedures

Nov 16, 2017

Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has successfully registered Tri-Solfen in New Zealand for sheep and cattle husbandry procedures. Tri-Solfen is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improve wound healing. Tri-Solfen was registered through the Ministry for Primary Industries, which leads and facilitates the management of animal welfare policy and practice in New Zealand.   Over one billion livestock animals globally undergo highly invasive painful husbandry procedures annually. Tri-Solfen is already registered in Australia separately for sheep and cattle husbandry procedures, where it is marketed and distributed by Bayer Animal Health, a global leader in animal health. To date, Tri-Solfen has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.   Animal Ethics accelerated the... ...

Read More

CVO – work to be done on antimicrobial use

Nov 13, 2017

Latest UK Veterinary Antibiotic Resistance and Sales Surveillance figures show antimicrobial use in food-producing animals has decreased. UK CVO Nigel Gibbens has urged small animal practitioners to take “a hard look” at the way they prescribe antimicrobials, following the publication of the latest UK Veterinary Antibiotic Resistance and Sales Surveillance (VARSS) figures that show antimicrobial use in food-producing animals has fallen by more than 27% in the last two years – the lowest level since records began. A drop in usage from 62mg/kg in 2014 to 45mg/kg in 2016 means a Government target of 50mg/kg – set following recommendations in the 2016 O’Neill Review on antimicrobial resistance – has been hit two years ahead of schedule. While Prof Gibbens welcomed the reduction in usage of antimicrobials in the farming sector, he was quick to point out more work needed to be done, particularly in the companion and equine sector, where he said figures were “not great”. “We won’t forget we need to deal with that,” Prof Gibbens commented at the Responsible Use... ...

Read More

Veterinary/Animal Vaccines Market to Grow at 5.9% CAGR to 2022 Led by Europe – ReportsnReports

Nov 13, 2017

Veterinary/Animal Vaccines Market Size will reach $8.66 billion by 2022 from $6.50 billion in 2017 at a CAGR of 5.9% between (2017-2022) driven by the growth in livestock population and repeated breakouts of livestock diseases; increasing adoption of companion animals; rising incidence of zoonotic diseases; initiatives by various government agencies, animal associations, and leading players; and the introduction of new types of vaccines in the market. The key players in the veterinary vaccines market are Zoetis (US), Merck Animal Health (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva (France), Phibro Animal Health (US), and Virbac (France). Other notable players operating in this market include Vetoquinol (France), Hester (India), Hipra (Spain), IDT Biologika (Germany), China Animal Husbandry (China), Biogenesis Bago (Argentina), Tianjin Ringpu (China), and Jinyu Bio-technology (China). Geographically, Europe is the largest market for veterinary vaccines market, followed by North America but the APAC region is expected to witness the highest growth in the forecast period. This growth is primarily attributed to rising pet adoption, expansion of key vaccine players in... ...

Read More